Glenmark gest final OK from USFDA for, Telmisartan and Hydrochlorothiazide tablets, its generics of Boehringer Micardis HCT tablets

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets, generic version of Micardis¹ HCT Tablets, of Boehringer Ingelheim Pharmaceuticals

Glenmark said in the announcement that, according to IQVIA sales data for the 12 month period ending January 2019, the Micardis HCT Tablets market achieved annual sales of approximately $40.6 million.

Glenmark’s current portfolio consists of 150 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA.

In addition to these internal filings, Glenmark said it continues seeking external development partnerships to boost its the growth.